JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Novel signature of ferroptosis-related long non-coding RNA to predict lower-grade glioma overall survival

  • 0Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, 420 Fuma Rd, Jin'an District, Fuzhou, 350011, Fujian, China.
Discover Oncology +

|

November 28, 2024

|

November 28, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A novel ferroptosis-related long non-coding RNA (FRlncRNA) risk score predicts lower-grade glioma (LGG) prognosis. This FRlncRNA score identifies high-risk patients with worse survival and distinct molecular and immune characteristics.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • Ferroptosis, a programmed cell death mechanism, plays a role in various tumors, but its underlying mechanisms are not fully understood.
  • Lower-grade glioma (LGG) prognosis prediction and understanding its molecular drivers are critical for effective treatment strategies.

Purpose Of The Study

  • To develop a prognostic risk score based on ferroptosis-related long non-coding RNAs (FRlncRNAs) for lower-grade glioma (LGG).
  • To explore the functional implications and potential mechanisms associated with the identified FRlncRNAs in LGG.

Main Methods

  • Utilized RNA sequencing data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases.
  • Identified FRlncRNAs using Pearson correlation and univariate Cox regression, then selected prognostic FRlncRNAs via intersection analysis.
  • Developed a risk score model using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression for LGG prognosis prediction.

Main Results

  • A panel of nine FRlncRNAs was identified to construct a novel prognostic risk score for LGG.
  • Patients with a high-risk score exhibited significantly worse overall survival compared to those with a low-risk score in both TCGA and CGGA datasets.
  • The risk score correlated with key clinicopathological characteristics and immune features, including B-cell and T-cell receptor signaling, immune cells (macrophages, CD4+ T cells), tumor microenvironment scores, and immune checkpoints (PD-1, PD-L1, CTLA4).

Conclusions

  • The developed nine FRlncRNA risk score serves as a promising biomarker for predicting LGG prognosis.
  • This risk score effectively distinguishes molecular and immune characteristics within LGG, offering insights into tumor heterogeneity and potential therapeutic targets.

Keywords: